Headlines
Novo Nordisk says Metsera bid won't raise antitrust issues
Published by Global Banking and Finance Review
Posted on November 3, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on November 3, 2025
COPENHAGEN (Reuters) -Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
Novo Nordisk last week launched a rival bid for obesity biotech Metsera, exceeding an offer from Pfizer as the drugmakers jostled for advantage in the highly lucrative market for weight-loss medications.
Pfizer in turn filed a lawsuit on Friday alleging breach of merger agreement obligations.
Novo Nordisk said it adhered to all the Pfizer merger agreement restrictions.
"This is an intensely competitive space, with at least a dozen other products being developed by major pharma companies. We are confident this transaction does not raise any antitrust issues," Novo said in an email statement.
Novo Nordisk, the company behind the blockbuster weight-loss drug Wegovy and related diabetes treatment Ozempic, bid up to $8.5 billion, with $6 billion upfront and later milestone payments, while Pfizer's bid was worth up to $7.3 billion, including milestones.
The clash marks an escalating battle for dominance in the obesity drug market some analysts forecast will reach $150 billion annually within a few years. Novo is seeking to defend its position against rising competition from Eli Lilly, while Pfizer aims to secure its entry into the weight-loss sector.
Metsera is working on experimental therapies that analysts say could generate $5 billion in sales.
Pfizer said Novo's bid was an illegal attempt by a dominant player to suppress competition in the fast-growing obesity market. Both Metsera and Novo have dismissed Pfizer's claims.
(Reporting by Jacob Gronholt-Pedersen and Essi Lehto; Editing by Terje Solsvik and Bill Berkrot)